Clinical Data Posts Flat Q4 Revenues; Files for $27.8M Public Offering bi13510964 NEW YORK (GenomeWeb News) Data reported after the close of the market Tuesday preliminary results for fourth quarter and fiscal-year 2010, and separately announced a public offering of common stock

Clinical Data, Inc. Prices $27.8M Common Offering bi13510964 NEWTON, Mass. -- Data, Inc. (NASDAQ: CLDA) today announced that has raised gross proceed..

Clinical Data raises $27.8M through stock sale bi13510964 Biotechnology company Data Inc. said Wednesday raised $27.8 million through the sale of 1.9 million shares. The company may raise another $4.2 million the underwriters of offer exercise an option to buy another 292,000 shares

Clinical Data raises $27.8 million through common stock public offering bi13510964 Data, Inc. today announced that has raised gross proceeds of approximately $27.8 million through the public offering of 1,945,576 newly issued shares of common stock at a price of $14.30 per share. All of the shares are being offered by Data, Inc., exhausts all remaining shares on existing shelf registration statement

Clinical Data, Inc. Prices Public Offering of Common Stock bi13510964 NEWTON, Mass.---- Data, Inc. today announced that has raised gross proceeds of approximately $27.8 million through the public offering of 1,945,576 newly issued shares of common stock at a price of $14.30 per share

Clinical Data prices $28M stock offering bi13510964 Data Inc., develops early- and late-stage targeted therapeutics and genetic and pharmacogenomic tests, has taken about $27.8 million after a public stock offering of 1.95 million shares priced at $14.30 per share

Clinical Data, Inc. Announces Public Offering of Common Stock bi13510964 NEWTON, Mass.---- Data, Inc. today announced that intends to offer all remaining shares of common stock on existing shelf registration statement an underwritten public offering

Clinical Data, Inc. Announces Data Confirming the Value of FCGR3A Gene Varian bi13510964 NEWTON, Mass.---- Data, Inc. , today announced that data from a study of the Fc gamma 3A receptor patients follicular non-Hodgkins lymphoma validates the use of genotyping for genetic variants the Fc gamma receptors for predicting response to rituximab

Geron Presents Clinical Data On Its Telomerase Inhibitor Drug In Breast Cance bi13510964 Geron Corporation (Nasdaq:GERN) announced the presentation of data from the trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, combination paclitaxel and bevacizumab patients breast cancer at the 2010 American Society of Oncology (ASCO) annual meeting Chicago. An interim analysis of the Phase 1 trial was presented by Geron ..

New Clinical Data On Millennium Solid Tumor Compounds Presented At American S bi13510964 Millennium: The Takeda Oncology Company announced data from trials of four investigational compounds solid tumors presented at the Annual Meeting of the American Society of Oncology (ASCO), held Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor. First data were presented for ..

FDA review finds flaws clinical trial for diabetes drug Avandia - Boston G bi13510964 Daily MailFDA review finds flaws trial for diabetes drug AvandiaBoston GlobeBy Christopher Rowland, Globe Staff WASHINGTON ? A key trial that drug maker GlaxoSmithKline has relied upon to defend the risk profile of Avandia, US experts urge limits for some drug safety trialsReutersFDA to consider fate of diabetes drug AvandiaUSA TodayFDA pokes holes study defending AvandiaCNN (blog)FiercePharma -Kansas City Star -Nature.com (blog)all 713 news articles »..

Auxilium Pharmaceuticals to Host Conference Call to Discuss XIAFLEX(R) Launch bi13510964 Auxilium Pharmaceuticals to Host Conference Call to Discuss XIAFLEX(R) Launch MarketWatch (press release)Dr. Clayton Peimer, Professor of Orthopedics at Michigan State University and attending hand surgeon at Marquette General Health System, and more »..

Biogen and partner advance hemophilia drug - BusinessWeek bi13510964 Biogen and partner advance hemophilia drugBusinessWeekBiogen Idec Inc. and Swedish Orphan Biovitrum said Friday they continue testing of a potential hemophilia drug based on promising results from Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long National Post (registration) (blog)Biogen Idec drug advances to new trialBoston GlobeBiogen, Swedish pharma advance hemophilia A drug to trialMass High TechDaily Marketsall 50 news articles »..

Genuine Honda Accessories - Home